Detalhe da pesquisa
1.
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Hepatology
; 78(5): 1558-1568, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37184202
2.
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
Hepatol Res
; 2023 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38018304
3.
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.
Hepatol Res
; 52(1): 105-119, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34626450
4.
Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients.
Int J Clin Oncol
; 26(5): 922-932, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730200
5.
Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: a case control study.
BMC Gastroenterol
; 20(1): 371, 2020 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167879
6.
The First Successful Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure Caused by Severe Acute Necrotizing Pancreatitis: A Case Report.
Transplant Proc
; 56(1): 239-243, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38218698
7.
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
J Clin Oncol
; 42(7): 790-799, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175991
8.
Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.
Aliment Pharmacol Ther
; 59(6): 742-751, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38173278
9.
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Cancers (Basel)
; 15(5)2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900359
10.
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Hepatol Commun
; 6(5): 1198-1212, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34837478
11.
Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019.
Sci Rep
; 12(1): 1517, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35087153
12.
Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.
Cancer Med
; 8(5): 2646-2653, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30900818
13.
Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study.
Hepatol Int
; 13(3): 293-301, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30820753
14.
Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
Biosci Trends
; 10(6): 496-499, 2017 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27990005
15.
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Cancer Med
; 4(8): 1214-23, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26044168